Until such large sets of intron-inclusion/retention transcriptomic data and/or isoform-specific proteomic data are made available on the same established (patient-derived) cancer cell lines, we can only assume, with an high level of confidence, that the IGF2 cancer-specific isoform variant is present at variable levels in the available datasets, with the highest probability in those cells with higher IGF2 relative transcript expression and with a growing correlation from the transcript to the protein level. Here, IGF2 is linked to cancer.